These results underscore the need for disease-specific understanding of tumor-associated macrophages and suggest that therapeutic strategies targeting the inflammatory axis, rather than conventional M2-targeted approaches, may be more relevant in JAK2-positive MPNs. The gene discussed is JAK2; the disease is neoplasm.